Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Status:
Enrolling by invitation
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in
all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of
the GIVINOSTAT studies.